The Immateriality of Circulating GDF11

Circulation Research

Volumn 118, Issue 10, 2016, Pages 1472-1474

  Rodgers, Buel D ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

aging; cardiomegaly; growth differentiating factor 11; ligands; myostatin

Indexed keywords

ACTIVIN RECEPTOR 2B; AGENTS AFFECTING METABOLISM; GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; LIGAND; MYOSTATIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GDF11 PROTEIN, HUMAN;

BINDING AFFINITY; CROSS REACTION; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; STRIATED MUSCLE; VALIDITY; VASCULAR REMODELING; AGING; ANIMAL; BLOOD; PATHOLOGY;

AGING; ANIMALS; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; GROWTH DIFFERENTIATION FACTORS; HUMANS; LIGANDS; MYOSTATIN;

EID: 84968813693     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308478     Document Type: Review

References (21)

1. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630-634. doi: 10. 1126/science. 1251141.
2. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344:649-652. doi: 10. 1126/science. 1251152.
3. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828-839. doi: 10. 1016/j. cell. 2013. 04. 015.
4. Sako D, Grinberg AV, Liu J, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem. 2010;285:21037-21048. doi: 10. 1074/jbc. M110. 114959.
5. McPherron AC, Huynh TV, Lee SJ. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol. 2009;9:24. doi: 10. 1186/1471-213X-9-24.
6. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet. 1999;22:260-264. doi: 10. 1038/10320.
7. Egerman MA, Cadena SM, Gilbert JA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;22:164-174. doi: 10. 1016/j. cmet. 2015. 05. 010.
8. Smith SC, Zhang X, Zhang X, et al. GDF11 does not rescue aging-related pathological hypertrophy. Circ Res. 2015;117:926-932. doi: 10. 1161/ CIRCRESAHA. 115. 307527.
9. Rodgers BD, Eldridge JA. Reduced circulating GDF11 is unlikely responsible for age-dependent changes in mouse heart, muscle, and brain. Endocrinology. 2015;156:3885-3888. doi: 10. 1210/en. 2015-1628.
10. Poggioli T, Vujic A, Yang P, et al. Circulating growth differentiation factor 11/8 levels decline with age. Circ Res. 2016;118:29-37. doi: 10. 1161/ CIRCRESAHA. 115. 307521.
11. Kerr T, Roalson EH, Rodgers BD. Phylogenetic analysis of the myostatin gene sub-family and the differential expression of a novel member in zebrafish. Evol Dev. 2005;7:390-400. doi: 10. 1111/j. 1525-142X. 2005. 05044. x.
12. Lakshman KM, Bhasin S, Corcoran C, Collins-Racie LA, Tchistiakova L, Forlow SB, St Ledger K, Burczynski ME, Dorner AJ, Lavallie ER. Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol. 2009;302:26-32. doi: 10. 1016/j. mce. 2008. 12. 019.
13. McNally EM. Questions and answers about myostatin, GDF11, and the aging heart. Circ Res. 2016;118:6-8. doi: 10. 1161/CIRCRESAHA. 115. 307861.
14. Kaiser J. Antiaging protein is the real deal, Harvard team claims. Science. October 21, 2015. doi: 10. 1126/science. Aad4748. http://www. sciencemag. org/news/2015/10/antiaging-protein-real-deal-harvard-team-claims.
15. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002;227:724-752.
16. Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P, Rodgers BD. Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis. Endocrinology. 2011;152:172-180. doi: 10. 1210/en. 2010-0488.
17. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, Molkentin JD. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121:419-425. doi: 10. 1161/CIRCULATIONAHA. 109. 882068.
18. Lee YS, Huynh TV, Lee SJ. Paracrine and endocrine modes of myostatin action. J Appl Physiol (1985). 2016;120:592-598. doi: 10. 1152/ japplphysiol. 00874. 2015.
19. Jackson MF, Li N, Rodgers BD. Myostatin regulates tissue potency and cardiac calcium-handling proteins. Endocrinology. 2014;155:1771-1785. doi: 10. 1210/en. 2013-2014.
20. Morissette MR, Cook SA, Foo S, McKoy G, Ashida N, Novikov M, Scherrer-Crosbie M, Li L, Matsui T, Brooks G, Rosenzweig A. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res. 2006;99:15-24. doi: 10. 1161/01. RES. 0000231290. 45676. d4.
21. Rodgers BD, Interlichia JP, Garikipati DK, Mamidi R, Chandra M, Nelson OL, Murry CE, Santana LF. Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling. J Physiol. 2009;587:4873-4886. doi: 10. 1113/jphysiol. 2009. 172544.